REG - Burning Rock Biotech - Burning Rock Reports 1st Quarter Financial Results
30/05/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230530:nRSd9883Aa&default-theme=true
RNS Number : 9883A Burning Rock Biotech Limited 30 May 2023
Burning Rock Reports First Quarter 2023 Financial Results
GUANGZHOU, China, May 30, 2023-Burning Rock Biotech Limited (NASDAQ: BNR and
LSE: BNR, the "Company" or "Burning Rock"), a company focused on the
application of next generation sequencing (NGS) technology in the field of
precision oncology, today reported financial results for the three months
ended March 31, 2023.
Recent Business Updates
· Minimal Residual Disease (MRD)
o Results of the MEDAL (MEthylation Based Dynamic Analysis for Lung Cancer)
study were published at the American Association for Cancer Research Annual
Meeting 2023 ("AACR 2023"). Through parallel testing and comparison of Burning
Rock's personalized MRD test brPROPHET™ and fixed MRD assays, the objective
of this study was to establish the best technique and application strategy of
dynamic MRD detection for prognosis prediction and disease assessment among
NSCLC patients. It shows that brPROPHET™ detected more MRD events with
ultra-low ctDNA abundance yet meaningful prognostic significance. In addition,
the dynamic change of longitudinal MRD was evaluated to explore the positive
predictive value (PPV) and negative predictive value (NPV) of MRD detections
over time, providing important insights for guiding the standardization of
future surveillance applications.
o The results of the clinical performance of brPROPHET™ in patients with
resectable gastric cancer and biliary tract cancer were also released at AACR
2023.
· Pharma Services
o Total value of new contracts entered into during the first quarter of 2023
amounted to RMB75 million, representing a 27% increase from the same period in
2022.
First Quarter 2023 Financial Results
Revenues were RMB142.5 million (US$20.8 million) for the three months ended
March 31, 2023, representing a 5.2% increase from RMB135.5 million for the
same period in 2022.
· Revenue generated from central laboratory business was RMB61.8
million (US$9.0 million) for the three months ended March 31, 2023,
representing a 16.7% decrease from RMB74.2 million for the same period in
2022, primarily attributable to a drop in the number of tests performed
resulting from the impact of COVID-19 pandemic in January and the Company's
focus on its in-hospital business.
· Revenue generated from in-hospital business was RMB51.6 million
(US$7.5 million) for the three months ended March 31, 2023, representing a
5.3% increase from RMB49.0 million for the same period in 2022, driven by an
increase in sales volume.
· Revenue generated from pharma research and development services
was RMB29.2 million (US$4.3 million) for the three months ended March 31,
2023, representing a 135.5% increase from RMB12.4 million for the same period
in 2022, primarily attributable to a further increased testing volume
performed and higher average total contract value from our existing and new
customers.
Cost of revenues was RMB43.7 million (US$6.4 million) for the three months
ended March 31, 2023, representing a 8.8% decrease from RMB47.9 million for
the same period in 2022, primarily due to a decrease in cost of central
laboratory business, which was in line with the decrease in revenue generated
from this business.
Gross profit was RMB98.8 million (US$14.4 million) for the three months ended
March 31, 2023, representing a 12.8% increase from RMB87.6 million for the
same period in 2022. Gross margin was 69.3% for the three months ended March
31, 2023, compared to 64.6% for the same period in 2022. By channel, gross
margin of central laboratory business was 77.8% for the three months ended
March 31, 2023, compared to 68.1% during the same period in 2022, primarily
due to a decrease in inventory write down and royalty fee; gross margin of
in-hospital business was 66.7% for the three months ended March 31, 2023,
compared to 68.2% during the same period in 2022; gross margin of pharma
research and development services was 55.8% for the three months ended March
31, 2023, compared to 29.2% during the same period of 2022, primarily due to
an increase in test volume of higher margin projects.
Non-GAAP gross profit, which excludes depreciation and amortization expenses,
was RMB107.9 million (US$15.7 million) for the three months ended March 31,
2023, representing a 16.4% increase from RMB92.7 million for the same period
in 2022. Non-GAAP gross margin was 75.7% for the three months ended March 31,
2023, compared to 68.4% for the same period in 2022.
Operating expenses were RMB287.2 million (US$41.8 million) for the three
months ended March 31, 2023, representing a 18.0% decrease from RMB350.4
million for the same period in 2022. The decrease was primarily driven by
budget control measures and headcount reduction to improve the Company's
operating efficiency.
· Research and development expenses were RMB94.4 million
(US$13.7 million) for the three months ended March 31, 2023, representing an
21.0% decrease from RMB119.5 million for the same period in 2022, primarily
due to (i) a decrease in research and development personnel's staff cost, and
(ii) a decrease in royalty and license fee.
· Selling and marketing expenses were RMB64.8 million (US$9.4
million) for the three months ended March 31, 2023, representing a 27.4%
decrease from RMB89.2 million for the same period in 2022, primarily due to
(i) a decrease in staff cost resulted from the reorganization of the sales
department and improvement in operating efficiency; (ii) a decrease in
entertainment and travel expenses; and (iii) a decrease in advertising and
marketing fee.
· General and administrative expenses were RMB128.0 million
(US$18.6 million) for the three months ended March 31, 2023, representing a
9.7% decrease from RMB141.7 million for the same period in 2022, primarily due
to (i) a decrease in general and administrative personnel's staff cost, and
(ii) a decrease in operating lease expense as a portion of the expense started
to be recognized as cost of revenue following the commencement of production
activities in the relevant parts of the property in the first half of 2022;
(iii) a decrease in amortized expense on share-based compensation.
Net loss was RMB185.3 million (US$27.0 million) for the three months ended
March 31, 2023, compared to RMB261.4 million for the same period in 2022.
Cash, cash equivalents, restricted cash and short-term investments were
RMB803.1 million (US$116.9 million) as of March 31, 2023.
2023 Financial Guidance
We reiterate our 2023 full-year revenue guidance of approximately 20% growth
over 2022.
Conference Call Information
Burning Rock will host a conference call to discuss the first quarter 2023
financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on
May 30, 2023.
Please register in advance of the conference using the link provided below and
dial in 15 minutes prior to the call, using participant dial-in numbers and
unique registrant ID which would be provided upon registering.
PRE-REGISTER LINK:
https://register.vevent.com/register/BI70acdaea8afc4d3e8f3eec70e5cc3fa7
(https://register.vevent.com/register/BI70acdaea8afc4d3e8f3eec70e5cc3fa7) .
Additionally, a live and archived webcast of the conference call and
presentation slides will also be available on the company's investor relations
website at http://ir.brbiotech.com (http://ir.brbiotech.com) or through link
https://edge.media-server.com/mmc/p/p3h6zb7y
(https://edge.media-server.com/mmc/p/p3h6zb7y) .
A replay of the webcast will be available for 12 months via the same link
above.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR), whose mission is to
guard life via science, focuses on the application of next generation
sequencing (NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage cancer
patients, and ii) cancer early detection, which has moved beyond
proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements
constitute "forward-looking" statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in the U.S.
Private Securities Litigation Reform Act of 1995. These forward-looking
statements can be identified by terminology such as "will," "expects,"
"anticipates," "future," "intends," "plans," "believes," "estimates,"
"target," "confident" and similar statements. Burning Rock may also make
written or oral forward-looking statements in its periodic reports to the SEC,
in its annual report to shareholders, in press releases and other written
materials and in oral statements made by its officers, directors or employees
to third parties. Statements that are not historical facts, including
statements about Burning Rock's beliefs and expectations, are forward-looking
statements. Such statements are based upon management's current expectations
and current market and operating conditions, and relate to events that involve
known or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock's control.
Forward-looking statements involve risks, uncertainties and other factors that
could cause actual results to differ materially from those contained in any
such statements. All information provided in this press release is as of the
date of this press release, and Burning Rock does not undertake any obligation
to update any forward-looking statement as a result of new information, future
events or otherwise, except as required under applicable law.
Non-GAAP Measures
In evaluating the business, the company considers and uses non-GAAP measures,
such as non-GAAP gross profit and non-GAAP gross margin, as supplemental
measures to review and assess operating performance. The presentation of these
non-GAAP financial measures is not intended to be considered in isolation or
as a substitute for the financial information prepared and presented in
accordance with accounting principles generally accepted in the United States
of America ("U.S. GAAP"). The company defines non-GAAP gross profit as gross
profit excluding depreciation and amortization. The company defines non-GAAP
gross margin as gross margin excluding depreciation and amortization.
The company presents these non-GAAP financial measures because they are used
by management to evaluate operating performance and formulate business plans.
The company believe non-GAAP gross profit and non-GAAP gross margin excluding
non-cash impact of depreciation and amortization reflect the company's ongoing
business operations in a manner that allows more meaningful period-to-period
comparisons.
Contact: IR@brbiotech.com
Selected Operating Data
For the three months ended
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
Central Laboratory Channel:
Number of patients tested 7,743 8,060 7,989 6,419 6,139
Number of ordering physicians((1)) 994 767 897 797 792
Number of ordering hospitals((2)) 318 264 257 238 241
((1)) Represents physicians who on average order at least one test from us every
month during a relevant period in the central laboratory channel.
((2)) Represents hospitals whose residing physicians who on average order at least
one test from us every month during a relevant period in the central
laboratory channel.
As of
March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
In-hospital Channel:
Pipeline partner hospitals((1)) 24 25 22 28 29
Contracted partner hospitals((2)) 41 43 47 49 49
Total number of partner hospitals 65 68 69 77 78
((1)) Refers to hospitals that are in the process of establishing in-hospital
laboratories, laboratory equipment procurement or installation, staff training
or pilot testing using the Company's products.
((2)) Refers to hospitals that have entered into contracts to purchase the Company's
products for use on a recurring basis in their respective in-hospital
laboratories the Company helped them establish. Kit revenue is generated from
contracted hospitals.
((1))
Refers to hospitals that are in the process of establishing in-hospital
laboratories, laboratory equipment procurement or installation, staff training
or pilot testing using the Company's products.
((2))
Refers to hospitals that have entered into contracts to purchase the Company's
products for use on a recurring basis in their respective in-hospital
laboratories the Company helped them establish. Kit revenue is generated from
contracted hospitals.
Selected Financial Data
For the three months ended
Revenues March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
(RMB in thousands)
Central laboratory channel 74,211 78,597 89,992 71,970 61,804
In-hospital channel 48,957 34,177 49,636 42,526 51,561
Pharma research and development channel 12,356 18,072 15,003 27,741 29,151
Total revenues 135,524 130,846 154,631 142,237 142,516
For the three months ended
Gross profit March 31, 2022 June 30, 2022 September 30, 2022 December 31, 2022 March 31, 2023
(RMB in thousands)
Central laboratory channel 50,574 57,575 69,991 54,507 48,090
In-hospital channel 33,396 20,012 31,593 26,999 34,409
Pharma research and development channel 3,610 5,015 7,010 19,757 16,273
Total gross profit 87,580 82,602 108,594 101,263 98,772
For the three months ended
Share-based compensation expenses March 31, June 30, September 30, December 31, March 31, 2023
2022 2022 2022 2022
(RMB in thousands)
Cost of revenues 365 441 481 496 353
Research and development expenses 12,299 11,923 13,978 14,673 13,612
Selling and marketing expenses 1,774 2,158 2,346 2,247 1,606
General and administrative expenses 65,715 62,615 61,041 74,232 62,595
Total share-based compensation expenses 80,153 77,137 77,846 91,648 78,166
Burning Rock Biotech Limited
Unaudited Condensed Statements of Comprehensive Loss
(in thousands, except for number of shares and per share data)
For the three months ended
March 31, June 30, September 30, 2022 December 31,2022 March 31, 2023 March 31, 2023
2022 2022
RMB RMB RMB RMB RMB US$
Revenues 135,524 130,846 154,631 142,237 142,516 20,752
Cost of revenues (47,944) (48,244) (46,037) (40,974) (43,744) (6,370)
Gross profit 87,580 82,602 108,594 101,263 98,772 14,382
Operating expenses:
Research and development expenses (119,496) (92,112) (109,433) (100,827) (94,417) (13,748)
Selling and marketing expenses (89,211) (105,634) (90,275) (85,174) (64,774) (9,432)
General and administrative expenses (141,733) (150,316) (143,530) (132,705) (128,039) (18,644)
Total operating expenses (350,440) (348,062) (343,238) (318,706) (287,230) (41,824)
Loss from operations (262,860) (265,460) (234,644) (217,443) (188,458) (27,442)
Interest income 1,832 2,685 2,001 2,838 3,144 458
Interest expenses 119 (29) 12 - - -
Other income (expense), net 298 127 (189) (84) 599 87
Foreign exchange (loss) gain, net (777) 624 1,337 365 (116) (17)
Loss before income tax (261,388) (262,053) (231,483) (214,324) (184,831) (26,914)
Income tax expenses - (84) - (1,901) (422) (61)
Net loss (261,388) (262,137) (231,483) (216,225) (185,253) (26,975)
Net loss attributable to Burning Rock Biotech Limited's shareholders (261,388) (262,137) (231,483) (216,225) (185,253) (26,975)
Net loss attributable to ordinary shareholders (261,388) (262,137) (231,483) (216,225) (185,253) (26,975)
Loss per share for class A and class B ordinary shares:
Class A ordinary shares - basic and diluted (2.50) (2.50) (2.23) （2.11) (1.81) (0.26)
Class B ordinary shares - basic and diluted (2.50) (2.50) (2.23) （2.11) (1.81) (0.26)
Weighted average shares outstanding used in loss per share computation:
Class A ordinary shares - basic and diluted 87,179,752 87,532,539 86,585,322 85,051,882 85,065,585 85,065,585
Class B ordinary shares - basic and diluted 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848
Other comprehensive income (loss), net of tax of nil:
Foreign currency translation adjustments (3,065) 29,715 20,646 (5,950) (5,659) (824)
Total comprehensive loss (264,453) (232,422) (210,837) (222,175) (190,912) (27,799)
Total comprehensive loss attributable to Burning Rock Biotech Limited's (264,453) (232,422) (210,837) (222,175) (190,912) (27,799)
shareholders
Burning Rock Biotech Limited
Unaudited Condensed Consolidated Balance Sheets
(In thousands)
As of
December 31, 2022 March 31, March 31,
2023 2023
RMB RMB US$
ASSETS
Current assets:
Cash and cash equivalents 905,451 793,484 115,540
Restricted cash 19,817 9,658 1,406
Accounts receivable, net 109,954 125,554 18,282
Contract assets, net 41,757 48,887 7,118
Inventories, net 130,321 113,895 16,584
Prepayments and other current assets, net 51,462 47,209 6,874
Total current assets 1,258,762 1,138,687 165,804
Non-current assets:
Equity method investment 690 599 87
Convertible note receivable 5,105 5,105 743
Property and equipment, net 251,829 220,342 32,084
Operating right-of-use assets 48,205 39,351 5,730
Intangible assets, net 1,986 1,701 248
Other non-current assets 20,890 11,583 1,687
Total non-current assets 328,705 278,681 40,579
TOTAL ASSETS 1,587,467 1,417,368 206,383
Burning Rock Biotech Limited
Unaudited Condensed Consolidated Balance Sheets (Continued)
(in thousands)
As of
December 31, 2022 March 31, March 31,
2023 2023
RMB RMB US$
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable 50,947 23,593 3,435
Deferred revenue 147,633 154,317 22,470
Accrued liabilities and other current liabilities 173,832 146,697 21,361
Customer deposits 1,803 1,197 174
Current portion of operating lease liabilities 37,236 32,312 4,705
Total current liabilities 411,451 358,116 52,145
Non-current liabilities:
Non-current portion of operating lease liabilities 13,551 9,144 1,331
Other non-current liabilities 4,124 4,545 661
Total non-current liabilities 17,675 13,689 1,992
TOTAL LIABILITIES 429,126 371,805 54,137
Shareholders' equity:
Class A ordinary shares 117 117 17
Class B ordinary shares 21 21 3
Additional paid-in capital 4,582,790 4,660,924 678,683
Treasury stock (58,919) (58,919) (8,579)
Accumulated deficits (3,199,946) (3,385,199) (492,923)
Accumulated other comprehensive loss (165,722) (171,381) (24,955)
Total shareholders' equity 1,158,341 1,045,563 152,246
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 1,587,467 1,417,368 206,383
Burning Rock Biotech Limited
Unaudited Condensed Statements of Cash Flows
(in thousands)
For the three months ended
March 31, 2022 March 31, 2023 March 31, 2023
RMB RMB US$
Net cash used in operating activities (144,361) (113,143) (16,475)
Net cash used in investing activities (13,011) (4,059) (591)
Net cash used in financing activities (3,934) (32) (5)
Effect of exchange rate on cash, cash equivalents and restricted cash (2,931) (4,892) (712)
Net decrease in cash, cash equivalents and restricted cash (164,237) (122,126) (17,783)
Cash, cash equivalents and restricted cash at the beginning of period 1,439,112 925,268 134,729
Cash, cash equivalents and restricted cash at the end of period 1,274,875 803,142 116,946
Burning Rock Biotech Limited
Reconciliations of GAAP and Non-GAAP Results
For the three months ended
March 31, June 30, September 30, 2022 December 31, March 31, 2023
2022 2022 2022
(RMB in thousands)
Gross profit:
Central laboratory channel 50,574 57,575 69,991 54,507 48,090
In-hospital channel 33,396 20,012 31,593 26,999 34,409
Pharma research and development channel 3,610 5,015 7,010 19,757 16,273
Total gross profit 87,580 82,602 108,594 101,263 98,772
Add: depreciation and amortization:
Central laboratory channel 2,553 2,545 3,138 3,609 2,567
In-hospital channel 93 1,428 2,479 2,449 2,582
Pharma research and development channel 2,493 4,327 2,805 3,065 3,974
Total depreciation and amortization included in cost of revenues 5,139 8,300 8,422 9,123 9,123
Non-GAAP gross profit：
Central laboratory channel 53,127 60,120 73,129 58,116 50,657
In-hospital channel 33,489 21,440 34,072 29,448 36,991
Pharma research and development channel 6,103 9,342 9,815 22,822 20,247
Total non-GAAP gross profit 92,719 90,902 117,016 110,386 107,895
Non-GAAP gross margin：
Central laboratory channel 71.6% 76.5% 81.3% 80.8% 82.0%
In-hospital channel 68.4% 62.7% 68.6% 69.2% 71.7%
Pharma research and development channel 49.4% 51.7% 65.4% 82.3% 69.5%
Total non-GAAP gross margin 68.4% 69.5% 75.7% 77.6% 75.7%
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END QRFAMMJTMTAJMIJRecent news on Burning Rock Biotech
See all newsREG - Burning Rock Biotech - Burning Rock Announces ADS Ratio Change
AnnouncementREG - Burning Rock Biotech - BNR Reports 23Q4 and Full Year Financial Results
AnnouncementREG - Burning Rock Biotech - BNR Announces Receipt of Notification from NASDAQ
AnnouncementREG - Burning Rock Biotech - BNR Announces Results of 2023 AGM
AnnouncementREG - Burning Rock Biotech - BNR Reports Third Quarter 2023 Financial Results
Announcement